DECKER, Barbora, Tomáš MLČOCH, Tomáš DOLEŽAL, Claudie CHARBONNEAU, Anita H. SUNG, Petra VOTHOVÁ, Pavol MAZAN and Sabina BILLOVÁ. Cost-effectiveness analysis of isavuconazole for the treatment of invasive aspergillosis in the Czech Republic. In ISPOR Europe 2018, Barcelona. 2018. ISSN 1098-3015. Available from: https://dx.doi.org/10.1016/j.jval.2018.09.1387.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cost-effectiveness analysis of isavuconazole for the treatment of invasive aspergillosis in the Czech Republic
Authors DECKER, Barbora, Tomáš MLČOCH, Tomáš DOLEŽAL, Claudie CHARBONNEAU, Anita H. SUNG, Petra VOTHOVÁ, Pavol MAZAN and Sabina BILLOVÁ.
Edition ISPOR Europe 2018, Barcelona, 2018.
Other information
Type of outcome Conference abstract
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.037
ISSN 1098-3015
Doi http://dx.doi.org/10.1016/j.jval.2018.09.1387
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/1/2023 09:13.
Abstract
Over a lifetime horizon, isavuconazole yields additional 0.30 QALYs (7.80 vs. 7.50) at the additional total cost of €3059 (€18,664 vs. €15,605) compared with SoC, with the incremental cost-effectiveness ratio of €10,251 per QALY. PSA showed that probability of isavuconazole to be cost-effective is 75% at the WTP threshold. OWSA and SA confirmed the robustness of the base-case result while the most influential parameters were mortality and prevalence of mucormycosis.
PrintDisplayed: 26/7/2024 16:28